Pyruvate kinase deficiency is a rare, hereditary, chronic condition that is associated with hemolytic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate ...

Chemists have developed an organic catalyst that can drive reactions using pyruvate -- a key biomolecule in many metabolic pathways -- that are difficult and complicated to achieve using conventional ...

Image Caption: Pyruvate inhibits TNFα/NF-κB signaling and the expression of downstream pro-inflammatory genes. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles ...

Scientists led by a team at the Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, have worked out how a molecular machine found in mitochondria—the “powerhouses” of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...